Neiry Group

Neiry Group operates across several neurotechnology markets rather than focusing on a single device category. Its portfolio combines brain-computer interfaces, clinical and research equipment, EEG-based training, biofeedback systems, neuromarketing tools, and neurotechnology for livestock applications. This breadth may let the group reuse capabilities in hardware, software, physiological-signal processing, and research across different customer settings, from clinical practice and education to consumer wellbeing and food production. The company identifies products such as Mind Tracker, Neurro, NeuroBOС, NeuroEEG, NeuroRoga, and NeuroTrend, and describes an API for integrating physiological signals from its devices. Its reported team of more than 300 experts spans medical, scientific, engineering, and technology roles. Its differentiation is therefore best assessed through portfolio breadth and the combination of device development, neurodata analysis, and applications across both human and animal use cases.

The funding history suggests an increase in financing scale: a 500 million ruble Series B in 2025, led by NTI Fund and Voskhod Fund, is followed by a listed 1 billion ruble Series C in 2026. The company’s valuation was stated as 4.25 billion rubles in 2025. Neiry’s growth strategy appears to extend across multiple product areas, including BCI hardware, EEG and functional-diagnostics equipment, neurofeedback and biofeedback software, neuromarketing systems, and cattle neurotechnology. Named offerings include Mind Tracker, Neurro, NeuroBOС, NeuroEEG, NeuroRoga, and NeuroTrend. Without dated launch, revenue, adoption, or headcount trend data, it is not possible to determine which products are driving growth or whether the expanding portfolio is translating into commercial scale.